Lunai Bioworks regains Nasdaq compliance after Oct 31 meeting

Lunai Bioworks Inc. reported that it has re‑established compliance with Nasdaq Listing Rule 5620(a) after holding its annual meeting of shareholders on October 31, 2025.

Accepted by SEC EDGAR 11/06/2025 - 04:22 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Lunai Bioworks Inc. reported that it has re‑established compliance with Nasdaq Listing Rule 5620(a) after holding its annual meeting of shareholders on October 31, 2025.

Nasdaq had notified the company on July 7, 2025 that it was not in compliance for not holding an annual meeting within one year of its fiscal year end. Following the October 31 meeting, Nasdaq determined the company now complies with the rule and closed the matter.

8-K Event Classification

Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

1 item

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities

The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did LNAI announce in this 8-K?

The company stated it re-established compliance with Nasdaq Listing Rule 5620(a) after holding its annual meeting on October 31, 2025.

Which Nasdaq rule was involved for LNAI?

Nasdaq Listing Rule 5620(a), which requires listed companies to hold an annual meeting no later than one year after the fiscal year end.

When was LNAI first notified of noncompliance?

Nasdaq sent a notice on July 7, 2025 stating the company was not in compliance with Rule 5620(a).

What action resolved LNAI’s noncompliance?

Holding the annual meeting of shareholders on October 31, 2025 resolved the issue.

What is Nasdaq’s current status for LNAI on this matter?

Nasdaq determined the company now complies with the rule and has closed the matter.

What is Lunai Bioworks’ trading symbol and listing venue?

Common stock trades under LNAI on The Nasdaq Stock Market LLC.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false 0001527728 0001527728 2025-11-04 2025-11-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 4, 2025

LUNAI BIOWORKS INC.

(Exact name of registrant as specified in its charter)

Delaware		001-38751		45-2259340
(State or other jurisdiction		(Commission File Number)		(I.R.S. Employer
of incorporation)				Identification No.)

2080 Century Park East, Suite 906

Los Angeles, CA 90067

 (Address of principal executive offices)

+1 (305) 918-1980

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol		Name of Each Exchange on Which Registered
Common Stock, par value $0.0001 per share		LNAI		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01(b): Notice of Re-establishment of Compliance

On July 7, 2025, Lunai Bioworks Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was no longer in compliance with Nasdaq Listing Rule 5620(a), which requires that listed companies hold an annual meeting of shareholders no later than one year after the end of their fiscal year. Based on the Company’s October 31, 2025 annual meeting, Nasdaq determined that the Company now complies with the Rule and has closed the matter.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	LUNAI BIOWORKS INC.
	By:	/s/ David Weinstein
		Name: David Weinstein Title: Chief Executive Officer

Date: November 6, 2025